NGNE
Neurogene Inc
30.90$
-7.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -100.0% | – | – | – | – | – | – | – | – | |
| – | +5.0% | -93.2% | -1.0% | +1,893.3% | -5.8% | +15.7% | +9.0% | -11.0% | -95.4% | +8.5% | – | – | |
| – | – | – | – | -15,178.7% | – | – | – | – | – | – | – | – | |
| – | +5.0% | +11.1% | +16.3% | +3.4% | -5.8% | +15.7% | +9.0% | -11.0% | +19.7% | +21.9% | +1.3% | – | |
| – | -29.4% | +105.5% | +1.5% | +10.9% | +4.6% | +32.3% | -17.7% | -2.4% | +5.1% | +19.0% | +36.6% | – | |
| – | -29.4% | +604.4% | +12.7% | -70.9% | +4.6% | +32.3% | -17.7% | -2.4% | +307.8% | +21.5% | +12.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -25.0% | +0.0% | +33.3% | -25.0% | -33.3% | +0.0% | -50.0% | +0.0% | +0.0% | -100.0% | – | – | |
| – | – | -810.1% | – | – | – | – | – | – | – | – | – | – | |
| – | +340.1% | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | -810.1% | – | – | – | – | – | – | – | – | – | – | |
| – | – | -600.7% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.